Eric Venker - 20 Jul 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: President & COO
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Issuer symbol: ROIV
Transactions as of: 20 Jul 2023
Net transactions value: -$2,927,290
Form type: 4
Filing time: 24 Jul 2023, 21:31:31 UTC
Previous filing: 26 Jun 2023
Next filing: 27 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$613,640	+159,387	+25%	$3.85	803,602	20 Jul 2023	Direct
transaction	ROIV	Common Shares	Sale	$1,802,667	-159,387	-20%	$11.31	644,215	20 Jul 2023	Direct	F1, F2
transaction	ROIV	Common Shares	Options Exercise	$700,692	+181,998	+28%	$3.85	826,213	21 Jul 2023	Direct
transaction	ROIV	Common Shares	Sale	$2,025,638	-181,998	-22%	$11.13	644,215	21 Jul 2023	Direct	F1, F2
transaction	ROIV	Common Shares	Options Exercise	$127,362	+33,081	+5.1%	$3.85	677,296	24 Jul 2023	Direct
transaction	ROIV	Common Shares	Sale	$361,575	-33,081	-4.9%	$10.93	644,215	24 Jul 2023	Direct	F1, F2
transaction	ROIV	Common Shares	Other	$179,104	-16,297	-2.5%	$10.99	627,918	24 Jul 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-159,387	-1%	$0.000000	15,163,797	20 Jul 2023	Common Shares	159,387	$3.85	Direct	F4
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-181,998	-1.2%	$0.000000	14,981,799	21 Jul 2023	Common Shares	181,998	$3.85	Direct	F4
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-33,081	-0.22%	$0.000000	14,948,718	24 Jul 2023	Common Shares	33,081	$3.85	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
F2	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3	Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. These sales was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
F4	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).